The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 7
- 7 new
- Median first-year cost
- $821,720
- $5,351,740 in all
- Institutions
- 6
- 7 contact PIs
Awards by fiscal year
0
0
0
0
0
0
0
0
7
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- JOSLIN DIABETES CENTER2
- MAYO CLINIC ROCHESTER1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- UNIVERSITY OF COLORADO DENVER1
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
and 1 other institution
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-Q (M1))4
- Special Emphasis Panel (ZHL1 CSR-Q (O1))3
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2022 | Apolipoprotein C3-loading of apolipoprotein B100 lipoproteins and cardiovascular disease in patients with type 1 diabetes1R01HL161829-01 | Heinecke, Jay W | UNIVERSITY OF WASHINGTON, WA | First-year cost $862,314 | Study section ZHL1 |
| FY2022 | Cholesterol reduction and cardiovascular risk in Type 1 diabetes1R01HL164949-01 | Goldberg, Ira J | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | First-year cost $861,449 | Study section ZHL1 |
| FY2022 | Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes1R01HL161864-01 | King, George L | JOSLIN DIABETES CENTER, MA | First-year cost $850,868 | Study section ZHL1 |
| FY2022 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes1R01HL161858-01 | Doria, Alessandro | JOSLIN DIABETES CENTER, MA | First-year cost $821,720 | Study section ZHL1 |
| FY2022 | Sorbs2 targeting and BK channel regulation in the coronary artery of patients with type 1 diabetes1R01HL161821-01A1 | Lu, Tong | MAYO CLINIC ROCHESTER, MN | First-year cost $688,424 | Study section ZHL1 |
| FY2022 | Examining Susceptibility and Resistance Phenotypes to Enhance Understanding of the Genetic Basis of Major Coronary Artery Disease in Type 1 Diabetes1R01HL161879-01A1 | Miller, Rachel Grace | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | First-year cost $648,834 | Study section ZHL1 |
| FY2022 | Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)1R01HL165433-01 | Bjornstad, PetterNadeau, Kristen Jane | UNIVERSITY OF COLORADO DENVER, CO | First-year cost $618,131 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.